Norman Lehman, MD
Pathology · Temple
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Scott and White Clinic · 2,426 clinicians in this group
Hospitals listed: Baylor Scott & White Medical Center - Temple · Scott & White Hospital-Round Rock. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lehman’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A55579 · Current
Licensed to practise in California · since 1996 · expires 2027-11-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas U6746Physician License · since 2023 · expires 2028-11-30ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Baylor Scott & White Medical Center - Round RockRound Rock, TXAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Baylor Scott and White Health, which runs 31 hospitalsPatients rate it 4 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Baylor Scott & White Medical Center - TempleTemple, TXAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Baylor Scott and White Health, which runs 31 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 3.26 (2.46 to 4.06) · 2,574 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.07 (0 to 0.5) · 9,785 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.155, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.51, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.183, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 1,361 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Baylor Scott & White Medical Center - Round Rock
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.78 (0 to 1.72) · 1,532 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.95 (0.65 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.02 (106.52 to 209.51) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 280 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.6 · 392 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.9 · 414 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 247 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 3,715 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.38) · 6,435 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 6,552 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (1.01 to 4.85) · 1,962 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.31 (0 to 2.85) · 1,007 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.8 to 3.63) · 1,839 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.15 (2.23 to 14.07) · 1,012 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.6 (2.18 to 9.01) · 982 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.92 (0.46 to 3.38) · 570 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.72 (0.05 to 1.39) · 5,047 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 47 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.498 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.682 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.808 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 392 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 596 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -8.3 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.7 · 422 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -16.8 · 414 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 531 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.8) · 269 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.4 (7.9 to 13.5) · 269 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 278 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.1 to 17.4) · 3,024 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 864 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,793 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 61% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Baylor Scott & White Medical Center - Temple
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 3.26 (2.46 to 4.06) · 2,574 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.07 (0 to 0.5) · 9,785 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.155 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.51 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.183 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 1,361 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.85 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.45 (122.81 to 198.08) · 223 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 80 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 217 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 134 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 430 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.8 · 681 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,613 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 10,902 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.35) · 11,298 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.48 (2.85 to 6.11) · 3,169 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.48 to 3.11) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (1.31 to 3.68) · 3,051 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.09 (7.35 to 16.82) · 1,217 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.9 (4.21 to 9.58) · 1,304 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.18 (0.83 to 3.54) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 207 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.715 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.745 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.834 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 294 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.3 · 869 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -28.3 · 157 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 12.4 · 542 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -1.6 · 467 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 760 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.6 to 6.1) · 567 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (7.8 to 11.7) · 567 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.1 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.8 · 578 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.1 to 15.9) · 2,741 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,016 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$5,069
Medicare paid this office $5,069 for 46 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Special stained specimen slides to examine tissue, each additional procedure | 17 | $1,670 | $21 |
| Pathology examination of tissue using a microscope, moderately high complexity | 18 | $1,524 | $61 |
| Special stained specimen slides to examine tissue, initial procedure | 17 | $443 | $26 |
| Microscopic genetic analysis of tumor, manual | 11 | $371 | $31 |
| Pathology examination of tissue using a microscope, moderately low complexity | 16 | $150 | $8 |
Who their Medicare patients are
46 Original Medicare patients in 2024. Average age 72 · Women 65% · Health risk score 1.11. At or below the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Stroke 35% · Depression 30% · Diabetes 28% · Cancer 28%.
The office billed $46,049, Medicare allowed $6,389 and paid $5,069; for 192 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 46 | 192 | 72 | 1.11 | $46,049 | $5,069 |
| 2023 | 80 | 235 | 71 | 1.28 | $43,701 | $5,852 |
| 2022 | 49 | 158 | 71 | 1.61 | $30,330 | $2,945 |
| 2021 | 79 | 239 | 69 | 1.45 | $49,840 | $6,692 |
| 2020 | 237 | 765 | 68 | 2.15 | $164,530 | $24,699 |
| 2019 | 534 | 1,950 | 68 | 1.88 | $466,603 | $68,817 |
| 2018 | 16 | 69 | 65 | 1.74 | $16,580 | $2,173 |
| 2017 | 44 | 249 | 69 | 1.44 | $48,231 | $9,161 |
| 2016 | 80 | 393 | 70 | 1.81 | $82,137 | $14,665 |
| 2015 | 68 | 464 | 67 | 1.83 | $75,838 | $13,735 |
| 2014 | 102 | 679 | 65 | 1.55 | $178,018 | $19,271 |
| 2013 | 99 | 577 | 66 | 1.35 | $125,874 | $23,277 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Pathology examination of tissue using a microscope, intermediate complexity | 45 | $2,299 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 11 | $1,051 | $62 |
| Special stained specimen slides to examine tissue, initial procedure | 12 | $367 | $26 |
| Pathology examination of tissue using a microscope, limited examination | 15 | $53 | $3 |
2022: 3 services
| Pathology examination of tissue using a microscope, intermediate complexity | 22 | $907 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 13 | $290 | $21 |
| Pathology examination of tissue using a microscope, moderately low complexity | 11 | $103 | $8 |
2021: 5 services
| Pathology examination of tissue using a microscope, moderately high complexity | 20 | $2,054 | $64 |
| Pathology examination of tissue using a microscope, intermediate complexity | 38 | $1,660 | $28 |
| Special stained specimen slides to examine tissue, each additional procedure | 14 | $1,181 | $20 |
| Special stained specimen slides to examine tissue, initial procedure | 21 | $599 | $26 |
| Pathology examination of tissue using a microscope, moderately low complexity | 16 | $151 | $8 |
2020: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 142 | $7,924 | $30 |
| Pathology examination of tissue using a microscope, moderately high complexity | 47 | $4,622 | $63 |
| Special stained specimen slides to examine tissue, each additional procedure | 37 | $3,030 | $22 |
| Pathology examination of tissue using a microscope, high complexity | 20 | $2,520 | $115 |
| Evaluation of fine needle aspirate with interpretation and report | 27 | $1,718 | $55 |
| Special stained specimen slides to examine tissue, initial procedure | 43 | $1,374 | $27 |
| Pathology examination of tissue using a microscope, moderately low complexity | 33 | $356 | $9 |
| Special stained specimen slides to identify organisms including interpretation and report | 11 | $345 | $20 |
| Cell examination of body fluid, smears | 13 | $293 | $23 |
| Cell examination of specimen, selective cellular enhancement technique | 13 | $289 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $225 | $10 |
| Preparation of tissue for examination by removing any calcium present | 15 | $169 | $10 |
2019: 17 services
| Pathology examination of tissue using a microscope, intermediate complexity | 296 | $17,827 | $30 |
| Pathology examination of tissue using a microscope, moderately high complexity | 129 | $16,507 | $65 |
| Pathology examination of tissue using a microscope, high complexity | 56 | $7,725 | $115 |
| Special stained specimen slides to examine tissue, each additional procedure | 88 | $7,250 | $23 |
| Pathology examination of specimen during surgery, first tissue block | 61 | $5,465 | $49 |
| Special stained specimen slides to examine tissue, initial procedure | 112 | $3,438 | $28 |
| Evaluation of fine needle aspirate with interpretation and report | 33 | $2,114 | $56 |
| Microscopic genetic analysis of tumor, manual | 15 | $1,003 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 87 | $876 | $9 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 13 | $852 | $66 |
| Pathology examination of specimen during surgery, each additional tissue block | 13 | $755 | $24 |
| Bone marrow, smear interpretation | 13 | $538 | $38 |
| Preparation of tissue for examination by removing any calcium present | 45 | $507 | $10 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $503 | $21 |
| Cell examination of specimen, selective cellular enhancement technique | 14 | $352 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $352 | $10 |
| Pathology examination of tissue using a microscope, limited examination | 25 | $91 | $3 |
2017: 4 services
| Pathology examination of tissue using a microscope, moderately high complexity | 29 | $3,955 | $67 |
| Special stained specimen slides to examine tissue, each additional procedure | 22 | $2,025 | $23 |
| Microscopic genetic analysis of tumor, manual | 22 | $1,054 | $44 |
| Special stained specimen slides to examine tissue, initial procedure | 29 | $941 | $29 |
2016: 6 services
| Pathology examination of tissue using a microscope, moderately high complexity | 51 | $6,662 | $67 |
| Special stained specimen slides to examine tissue, each additional procedure | 36 | $2,860 | $21 |
| Microscopic genetic analysis of tumor, manual | 34 | $1,559 | $43 |
| Special stained specimen slides to examine tissue, initial procedure | 46 | $1,366 | $28 |
| Pathology examination of tissue using a microscope, intermediate complexity | 22 | $972 | $30 |
| Pathology examination of specimen during surgery, first tissue block | 15 | $749 | $47 |
2015: 5 services
| Pathology examination of tissue using a microscope, moderately high complexity | 47 | $5,675 | $64 |
| Special stained specimen slides to examine tissue, each additional procedure | 40 | $3,736 | $16 |
| Special stained specimen slides to examine tissue, initial procedure | 47 | $1,590 | $27 |
| Microscopic genetic analysis of tumor, manual | 30 | $1,307 | $41 |
| Pathology examination of tissue using a microscope, intermediate complexity | 16 | $508 | $30 |
2014: 6 services
| Pathology examination of tissue using a microscope, moderately high complexity | 74 | $9,977 | $64 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 56 | $2,854 | $10 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 66 | $1,825 | $24 |
| Microscopic genetic analysis of tumor, manual | 35 | $1,688 | $42 |
| Pathology examination of tissue using a microscope, intermediate complexity | 20 | $979 | $29 |
| Pathology examination of specimen during surgery, first tissue block | 13 | $888 | $47 |
2013: 7 services
| Pathology examination of tissue using a microscope, moderately high complexity | 68 | $9,465 | $62 |
| Special stained specimen slides to examine tissue, initial procedure | 58 | $8,381 | $33 |
| Microscopic genetic analysis of tumor, manual | 43 | $1,898 | $40 |
| Pathology examination of specimen during surgery, first tissue block | 34 | $1,890 | $47 |
| Pathology examination of tissue using a microscope, intermediate complexity | 16 | $654 | $28 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $139 | $9 |
| Pathology examination of tissue using a microscope, moderately low complexity | 12 | $104 | $9 |
Medicaid work
$6,110 in 2023
Medicaid paid $6,110 for 119 billed services this clinician did in 2023, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 90 | $5,033 |
| TISSUE EXAM BY PATHOLOGIST | 29 | $1,076 |
| 2023 | 119 | 2 | 27 | $6,110 |
| 2021 | 23 | 1 | 20 | $1,067 |
| 2020 | 241 | 2 | 42 | $13,268 |
| 2019 | 726 | 7 | 62 | $33,715 |
| 2018 | 49 | 2 | 19 | $2,360 |
See the largest Medicaid services in earlier years
2021
| TISSUE EXAM BY PATHOLOGIST | 23 | $1,067 |
2020
| TISSUE EXAM BY PATHOLOGIST | 114 | $6,961 |
| TISSUE EXAM BY PATHOLOGIST | 127 | $6,307 |
2019
| TISSUE EXAM BY PATHOLOGIST | 272 | $17,390 |
| TISSUE EXAM BY PATHOLOGIST | 312 | $13,145 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 53 | $1,296 |
| Level VI surgical pathology with gross and microscopic examination | 15 | $860 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 14 | $515 |
| TISSUE EXAM BY PATHOLOGIST | 47 | $377 |
| DECALCIFICATION PROCEDURE | 13 | $132 |
2018
| TISSUE EXAM BY PATHOLOGIST | 33 | $1,747 |
| TISSUE EXAM BY PATHOLOGIST | 16 | $613 |
Money from drug and device companies
$42 in 2025
| 2025 | 1 | 1 | None | $42 |
| 2023 | 1 | 2 | None | $218 |
| 2019 | 1 | 1 | None | $17 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Straumann USA | None | $42 | 1 payment
|
See the published payment
| Straumann USA | Meals · 2025-01-21 | None | $42 |
See earlier years (2023, 2019)
2023: $218
| AstraZeneca Pharmaceuticals LP | Tagrisso | $218 | 2 payments
|
2019: $17
| Novocure | Oncology | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 73.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184768855
- Licence
- CA A55579, KY 50734, TX U6746California A55579: Current · expires 2027-11-30Texas U6746: Active
- Trained
- University of Southern California Keck School of Medicine, 1994
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A555790
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZN0500X (207ZN0500X)
- Mailing address
- Po Box 844658, Dallas, TX, 75284
- NPI first listed
- 2007-02-16
- NPI last updated
- 2024-02-14
- NPI record certified
- 2024-02-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr Rm L235, Stanford, CA, 94305
This office lists an electronic records connection.